BD and Biodiversity Collaborate on Molecular Diagnostic Menu

BD Diagnostics (Baltimore, MD, USA) and Biodiversity SpA (Brescia, Italy), a private biotechnology company focusing on molecular diagnostics, will collaborate to develop and commercialize a comprehensive molecular diagnostic menu for immunocompromised and transplant patients on the BD MAX System.

Representing the next generation in automated testing for molecular diagnostics, the BD MAX system enables walk away and on-demand workflow, fully automating cell lysis, nucleic acid extraction, polymerase chain reaction (PCR) set-up, amplification, and detection. The BD MAX system provides maximum testing flexibility, efficiency, and scalability for molecular testing in laboratories.

Biodiversity will develop a portfolio of molecular assays for the detection of infections in immunocompromised patients using the BD MAX system's open architecture. Assays developed are intended to be CE marked for sale and distribution in Europe, with future expansion to additional regions.

"This collaboration combines the BD MAX System's advanced automation and open system capabilities with Biodiversity's broad portfolio and track record at bringing to market molecular assays for the management of transplant patients," said Tom Polen, president, BD Diagnostics-Diagnostic Systems.

Following a transplant, patients are typically treated with drugs designed to suppress their immune system to prevent rejection. In this immunocompromised state, patients can be at high risk for infection. Early and accurate diagnosis of infection is often essential to monitor and protect patient health following a transplant procedure. Assays developed under the collaboration for the BD MAX system will expand testing capabilities for molecular laboratories with the ability to run many different assays and samples simultaneously, which can lead to faster testing results and potentially earlier diagnosis for patients

BD diagnostics is a segment of global medical technology company Becton, Dickinson and Company (BD). The company develops, manufactures, and sells medical devices, instrument systems and reagents.

Biodiversity is focused on molecular diagnostics as its core business, with a unique model providing integrated solutions to multiple molecular diagnostic-related areas. The company's objective is to develop, produce, and commercialize new molecular diagnostics products, services, and technologies in biomedical and clinical diagnostics, veterinary and animal science, agriculture and agro-food, and industrial microbiology.

Related Links:
BD Diagnostics
Biodiversity SpA